Abstract Hepatocellular carcinoma (HCC) is highly malignant, and most patients are diagnosed at intermediate or advanced stages. Current regimens, including surgery, targeted therapy and immune checkpoint inhibitors (ICIs), are limited by low response rates, drug resistance, prominent toxicities and high costs, so safe...
Li-Yuan Hao, Li-Wei Li, Yi-Cheng Chen et al.· Drug Design, Development and...· 0 citations
Preclinical and clinical therapeutic strategies targeting the metabolic-epigenetic microenvironment, viral assembly, antigen secretion, and cccDNA modulation to achieve a functional cure for HBV infection are summarized.
Qing Peng, Li-Yuan Hao, Sheng-Hao Li et al.· Frontiers in Microbiology· 0 citations
Aristolochic acid I (AAI) is a potent hepatocarcinogen mainly activated to aristolactam I (ALI). The molecular mechanisms driving ALI‑associated hepatocellular carcinoma (HCC), particularly post‑transcriptional events linking acute liver injury to malignant transformation, remain poorly defined. Here, we integrated pha...
Qing Peng, L. Hao, Sheng-Hao Li et al.· Ecotoxicology and Environmen...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.